Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

Zhao, Sizheng Steven, Harrison, Stephanie R., Chan, Antoni, Clarke, Nick, Davis, Charlotte, Eddison, Joe, Gregory, William J., Jones, Gareth T., Marzo-Ortega, Helena, Murphy, Daniel J., Sandhu, Virinderjit, Sengupta, Raj, Siebert, Stefan, Thompson, Ben, Webb, Dale, Yates, Max ORCID: https://orcid.org/0000-0003-3977-8920 and Gaffney, Karl ORCID: https://orcid.org/0000-0002-7863-9176 (2023) Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. Rheumatology Advances in Practice, 7 (2). ISSN 2514-1775

[thumbnail of rkad039]
Preview
PDF (rkad039) - Published Version
Available under License Creative Commons Attribution.

Download (612kB) | Preview

Abstract

Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug tapering. The aim of this guideline is to provide an evidence-based update on pharmacological management of adults with axSpA (including AS and non-radiographic axSpA) using b/tsDMARDs. This guideline is aimed at health-care professionals in the UK who care directly for people with axSpA, including rheumatologists, rheumatology specialist nurses, allied health professionals, rheumatology specialty trainees and pharmacists; people living with axSpA; and other stakeholders, such as patient organizations and charities.

Item Type: Article
Additional Information: Funding Information: S.S.Z. is supported by a National Institute for Health Research (NIHR) Clinical Lectureship and works in centres supported by Versus Arthritis (grant numbers 21173, 21754 and 21755). H.M.-O. is Chair and Trustee of the British Society for Spondyloarthritis (BRITSpA). H.M.-O. is supported by the NIHR Leeds Biomedical Research Centre (LBRC). The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the NIHR or the (UK) Department of Health.
Uncontrolled Keywords: as,axial spondyloarthritis,biologic,biosimilar,il17,jak inhibitor,switching,tapering,treat-to-target,rheumatology ,/dk/atira/pure/subjectarea/asjc/2700/2745
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Science > Research Groups > Norwich Epidemiology Centre
Faculty of Medicine and Health Sciences > Research Groups > Norwich Epidemiology Centre
Faculty of Medicine and Health Sciences > Research Centres > Population Health
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 01 Sep 2023 09:31
Last Modified: 19 Oct 2023 03:38
URI: https://ueaeprints.uea.ac.uk/id/eprint/92966
DOI: 10.1093/rap/rkad039

Actions (login required)

View Item View Item